Department of Immunology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Transpl Int. 2011 Feb;24(2):201-12. doi: 10.1111/j.1432-2277.2010.01185.x. Epub 2010 Nov 10.
Alloreactive NK cells (Allo-NKs) have been shown to exert advantageous effects on the outcomes of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) for cancer treatment. However, the mechanisms of action of Allo-NKs remain unclear. We established a novel Haplo-HSCT conditioning regimen composed of Allo-NKs and a low dose of immunosuppressive drugs (Allo-NKs + Chemo) to investigate alternative mechanisms besides direct cytotoxicity. The inhibitory effects of different cell subsets on the donor-recipient mixed lymphocyte reactions (MLRs) were evaluated after Haplo-HSCT. The quantities and functions of CD4(+) CD25(+) regulatory T cells (Tregs) and dendritic cells (DCs) in the spleen and the thymus were examined. Our results showed that the Allo-NKs + Chemo regimen induced systemic tolerance, and that CD4(+) CD25(+) Tregs played a significant role in inducing and maintaining systemic tolerance after Haplo-HSCT. Alloreactive NK cells promoted the expansion of recipient-derived CD4(+) CD25(+) CD127(-) Tregs in the thymus and the spleen which could be amplified in vitro by the immature donor-derived DC subset isolated from the thymus of Allo-NKs + Chemo-treated mice. Our findings suggested that Allo-NKs are capable of inducing systemic tolerance after Haplo-HSCT by assembling donor-derived immature DCs to expand recipient-derived Treg cells in the thymus.
同种异体反应性自然杀伤细胞(Allo-NK 细胞)已被证明对癌症治疗的单倍体造血干细胞移植(Haplo-HSCT)的结果具有有利影响。然而,Allo-NK 细胞的作用机制尚不清楚。我们建立了一种新的 Haplo-HSCT 预处理方案,由 Allo-NK 细胞和低剂量免疫抑制药物组成(Allo-NKs + 化疗),以研究除直接细胞毒性以外的替代机制。在 Haplo-HSCT 后评估不同细胞亚群对供体-受者混合淋巴细胞反应(MLRs)的抑制作用。检查脾和胸腺中 CD4(+) CD25(+)调节性 T 细胞(Tregs)和树突状细胞(DCs)的数量和功能。我们的结果表明,Allo-NKs + 化疗方案诱导全身耐受,CD4(+) CD25(+) Tregs 在 Haplo-HSCT 后诱导和维持全身耐受中起重要作用。同种异体反应性 NK 细胞促进受体衍生的 CD4(+) CD25(+) CD127(-) Tregs 在胸腺和脾脏中的扩增,这些细胞可以通过从接受 Allo-NKs + 化疗治疗的小鼠胸腺中分离的未成熟供体衍生的 DC 亚群在体外扩增。我们的研究结果表明,Allo-NK 细胞能够通过组装供体衍生的未成熟 DC 来扩增受体衍生的 Treg 细胞,从而在 Haplo-HSCT 后诱导全身耐受。